The Phenotyping Core will provide ORDRCC investigators with access to advanced high-content, cutting-edge biomolecular phenotyping services and datasets spanning genetic, genomic, proteomic, and functional cellular bioresponses on clinical samples available through the Clinical Characterization and Biorepository Core (CCBC) or from other ORDRCC Investigator projects. The tight integration of the Phenotyping Core and the CCBC within the ORDRCC enables both the efficient performance of phenotype characterizations and correlation of the clinical characteristics with molecular or cellular phenotypes on specific clinical samples. Consolidation of the range of technologies required for the complete characterization of a molecular or cellular phenotype into a single Core allows the Core to better assist all ORDRCC investigators in the efficient planning/design, execution and data analysis as dictated by their individual project needs. The Core is able to provide experience in performing research using clinical specimens, the necessary technical expertise in a wide range of molecular and bioassays, access to equipment and resources enabling cutting-edge approaches to address research questions, quality control assessment of the data collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations. Therefore, the goals of the Phenotyping Core can be summarized as follows: Goal 1: Offer expert consulting for experimental project design, cost analysis, implementation planning and project management for ORDRCC investigators. Goal 2: Provide access to advanced technology, centralized equipment and experienced personnel for high throughput/high content experimental phenotype characterization and biomarker assays in genetic, genomic, proteomic, immune phenotype and immune functional domains. Goal 3: Supply guidance on data quality control, processing of raw data, and preparation of data sets for more extensive statistical modeling. Goal 4: Assess and develop new cutting edge technologies for phenotype characterization.

Public Health Relevance

This Phenotyping Core provides ORDRCC investigators access to the technical expertise and resources to perform genetic, genomic, proteomic and cellular phenotype/function biomarker analyses required to develop a world class rheumatic disease focused clinical-translational research career.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oklahoma Medical Research Foundation
Oklahoma City
United States
Zip Code
Deng, Yun; Zhao, Jian; Sakurai, Daisuke et al. (2016) Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Ann Rheum Dis 75:2007-2013
Munroe, Melissa E; Young, Kendra A; Kamen, Diane L et al. (2016) Soluble Mediators and Clinical Features Discern Risk of Transitioning to Classified Disease in Relatives of Systemic Lupus Erythematosus Patients. Arthritis Rheumatol :
Wolska, Nina; Rybakowska, Paulina; Rasmussen, Astrid et al. (2016) Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif-Containing Protein 38 Show Greater Disease Severity. Arthritis Rheumatol 68:724-9
Vivino, Frederick B; Carsons, Steven E; Foulks, Gary et al. (2016) New Treatment Guidelines for Sjögren's Disease. Rheum Dis Clin North Am 42:531-51
Zhao, Jian; Giles, Brendan M; Taylor, Rhonda L et al. (2016) Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis 75:242-52
Smith, Kenneth; Shah, Hemangi; Muther, Jennifer J et al. (2016) Antigen nature and complexity influence human antibody light chain usage and specificity. Vaccine 34:2813-20
Munroe, Melissa E; Lu, Rufei; Zhao, Yan D et al. (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 75:2014-2021
Fayyaz, Anum; Kurien, Biji T; Scofield, R Hal (2016) Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am 42:419-34
Arriens, Cristina; Chen, Sixia; Karp, David R et al. (2016) Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol :
Ward, Julie M; Ratliff, Michelle L; Dozmorov, Mikhail G et al. (2016) Expression and methylation data from SLE patient and healthy control blood samples subdivided with respect to ARID3a levels. Data Brief 9:213-9

Showing the most recent 10 out of 212 publications